Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In
the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple …

The outbreak of coronavirus disease 2019 (COVID-19) posed an unprecedented challenge
on public health systems. Despite the measures put in place to contain it, COVID-19 is likely …

Patients with multiple myeloma (MM) were among the groups impacted more severely by the
COVID-19 pandemic, with higher rates of severe disease and COVID-19-related mortality …

We read with interest the recent review by Terpos et al. on management of COVID-19 in
multiple myeloma (MM) patients. We disagree with some of the authors recommendations …

B-cell maturation antigen (BCMA) is a promising therapeutic target for multiple myeloma
(MM). The aim of this study was to assess the effectiveness and tolerability of monotherapy …

Patients with multiple myeloma (MM) are a heterogenous, immunocompromised group with
increased risk for COVID-19 morbidity and mortality but impaired responses to primary …

COI notes: NF reported receiving grants from the American Heart Association (857078).
WBE reported receiving research grants (site PI for multicenter study) from Gilead Sciences …

COVID-19-related mortality in the onco-hematological setting is higher than in general
population, and patients with multiple myeloma (MM) have been reported to be particularly …

Patients affected by multiple myeloma (MM) have an increased risk of severe acute
respiratory syndrome coronavirus type 2 (SARS‐CoV‐2) infection and subsequent …

Teclistamab and other B-cell maturation antigen (BCMA)–targeting bispecific antibodies
(BsAbs) have substantial activity in patients with heavily pretreated multiple myeloma (MM) …